Strategies for managing the side effects of treatments for multiple sclerosis

Neurology

Volumn 63, Issue 11 SUPPL. 5, 2004, Pages

  Langer Gould, Annette ^a,d   Moses, Harold H ^b   Murray, T Jock ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Vanderbilt Stallworth Rehabilitation Hospital   (United States)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE;

ACNE; ALOPECIA; AMENORRHEA; ANXIETY DISORDER; ASEPTIC NECROSIS; BONE METABOLISM; CARDIOTOXICITY; CATARACT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; ERYTHEMA; FERTILITY; FLU LIKE SYNDROME; GLAUCOMA; HEADACHE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INFECTION; INFLAMMATION; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIPOATROPHY; LIVER DISEASE; LIVER TOXICITY; LONG TERM CARE; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MENSTRUATION DISORDER; METABOLIC DISORDER; MONITORING; MULTIPLE SCLEROSIS; MYALGIA; MYOPATHY; NECROSIS; NEUTROPENIA; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PAIN; PATIENT COMPLIANCE; PATIENT EDUCATION; PEPTIC ULCER; PHYSICIAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; THORAX PAIN; TOXICITY; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 10344225070     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.11_suppl_5.s35     Document Type: Review

References (55)

1. AVONEX® (Interferon beta-1a) package insert. Biegen Inc, Cambridge, MA; 2003.
2. Betaseron® (Interferon beta-1b) package insert. Berlex Laboratories, Montville, NJ; January 2002.
3. Rebif® (Interferon beta-1a) package insert. Ares-Serono, Geneva, Switzerland; March 2002.
4. Copaxone® (Glatiramer acetate injection) package insert. Teva Pharmaceutical Industries, Inc., Kansas City, MO; January 2002.
5. Novantrone® (Mitoxantrone for injection concentrate) package insert. Immunex Corporation, Seattle, WA; October 2002.
6. Arnoldus JHA, Killestein J, Pfennings LEMA, et al. Quality of life during the first 6 months of interferon-β treatment in patients with MS. Mult Scler 2000;6:338-342.
7. Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000;22:149-159.
8. Munschauer FE III, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-893.
9. Río J, Nos C, Marzo ME, Tintoré M, Montalban X. Low-dose steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998;50:1910-1912.
10. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler 2002;8:15-18.
11. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-236.
12. Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002;58(suppl 4):S10-22.
13. Mohr DC, Likosky W, Boudewyn AC, et al. Side effects profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998;4:487-489.
14. Schiffer RB, Caine ED, Bamford KA, Levy S. Depressive episodes in patients with multiple sclerosis. Am J Psychiatry 1983;140:1498-1500.
15. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426-434.
16. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol 1987;44:376-378.
17. Health Canada warns of liver complications from beta-interferon use for MS. The Canadian Press, 2003. http://www.cp.org/english/online/full/health/ 031218/x121842A.html. Accessed 2/10/2004.
18. Patten SB, Beck CA, Williams JVA, Barbui C, Metz ML. Major depression in multiple sclerosis. A population-based perspective. Neurology 2003;61:1524-1527.
19. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
20. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
21. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
22. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
23. Patten SB, Fridhandler S, Beck CA, Metz LM. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003;9:616-620.
24. Aikens JE, Fischer JS, Namey M, Rudick RA. A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis. J Behav Med 1997;20:433-445.
25. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-533.
26. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002;59:1496-1506.
27. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-661.
28. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
29. Río J, Marzo ME, Tintore M, Borras C, Montalban X. Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b. Neurologia 1998;13:422-426.
30. Tremlett H, Porciuncula J, Yoshida E, Paty D, Oger J. Post-marketing surveillance: liver test abnormalities during treatment with interferon b-1a(sc), -1a(im) and -1b(sc) in clinical practice. Neurology 2003;60(suppl 1):A55. Abstract.
31. Kreisler A, de Seze J, Stojkovic T, et al. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand 2003;107:154-157.
32. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
33. Korczyn AD, Nisipeanu P. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. J Neurol 1996;243(suppl 1):S23-26.
34. Pöllman W, Erasmus L-P, Feneberg W, Bergh FT, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002;59:636-639.
35. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2001;33:231-239.
36. Mancardi GL, Murialdo A, Drago F, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 2000;247:220-221.
37. Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis 2001;68:287-288.
38. Drago F, Brusati C. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol 1999;135:1277-1278.
39. Edgar CM, Brunet DG, Fenton P, et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58-63.
40. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety 2001;24:979-990.
41. Windhagen A, Maniak S, Marckmann S, et al. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate. J Neurol Neurosurg Psychiatry 2001;70:415-416.
42. Mauch E, Kornhuber HH. Immunosuppressive therapy of multiple sclerosis with mitoxantrone. Fortschr Neurol Psychiatr 1993;61:410-417.
43. Corboy JR, Goodin DS, Frohman EM. Disease-modifying therapies for multiple sclerosis. Curr Treat Options Neurol 2003;5:35-54.
44. Hartung H-P, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
45. Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401-1406.
46. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441-445.
47. Durelli L, Bergamini L. Multiple sclerosis. II. A critical assessment of immunotherapy. Riv Neurol 1989;59:191-201.
48. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516.
49. Stanbury RM, Graham EM. Systemic corticosteroid therapy - side effects and their management. Br J Ophthalmol 1998;82:704-708.
50. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247.
51. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-294.
52. Ardissone P, Rota E, Durelli L, et al. Effects of high doses of corticosteroids on bone metabolism. J Endocrinol Invest 2002;25:129-133.
53. Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991;21:1-11.
54. Nesbitt LT Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin 1995;13:925-939.
55. Imam AP, Halpern GM. Uses, adverse effects of abuse of corticosteroids. Part I. Allergol Immunopathol (Madr) 1994;22:250-260.